These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 19744163)

  • 21. Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma.
    Topkan E; Karaoglu A
    Oncology; 2006; 71(5-6):354-60. PubMed ID: 17873499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Facts and fiction in the pharmacologic prevention of post-ERCP pancreatitis: a never-ending story.
    Testoni PA
    Gastrointest Endosc; 2006 Nov; 64(5):732-4. PubMed ID: 17055866
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy of depot long-acting release octreotide therapy in severe dumping syndrome.
    Penning C; Vecht J; Masclee AA
    Aliment Pharmacol Ther; 2005 Nov; 22(10):963-9. PubMed ID: 16268971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial.
    Chrispijn M; Drenth JP
    Trials; 2011 Nov; 12():246. PubMed ID: 22104015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective administration of prophylactic octreotide during pancreaticoduodenectomy: a clinical and cost-benefit analysis in low- and high-risk glands.
    Vanounou T; Pratt WB; Callery MP; Vollmer CM
    J Am Coll Surg; 2007 Oct; 205(4):546-57. PubMed ID: 17903728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subtherapeutic dosing of methotrexate in rheumatoid arthritis trials.
    Parker CT; Mewshaw E; Dennis GJ
    J Am Osteopath Assoc; 2004 Jan; 104(1):7-8. PubMed ID: 14992316
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of everolimus on polycystic liver volume in autosomal dominant polycystic kidney disease.
    Zschiedrich S; Budde K; Walz G
    Clin Exp Nephrol; 2015 Aug; 19(4):757-8. PubMed ID: 25424440
    [No Abstract]   [Full Text] [Related]  

  • 28. Octreotide: a therapeutic option for idiopathic intracranial hypertension.
    Panagopoulos GN; Deftereos SN; Tagaris GA; Gryllia M; Kounadi T; Karamani O; Panagiotidis D; Koutiola-Pappa E; Karageorgiou CE; Piadites G
    Neurol Neurophysiol Neurosci; 2007 Jul; ():1. PubMed ID: 17700925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of hepatic polycystosis by intracystic injection of alcohol].
    Valette PJ; Chataing L; Partensky C; Paliard P
    Gastroenterol Clin Biol; 1987 Dec; 11(12):898-900. PubMed ID: 3449407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized intervention studies in human polycystic kidney and liver disease.
    Schrier RW
    J Am Soc Nephrol; 2010 Jun; 21(6):891-3. PubMed ID: 20431043
    [No Abstract]   [Full Text] [Related]  

  • 31. Octreotide enhances portal pressure reduction induced by propranolol in cirrhosis: a randomized, controlled trial.
    Vorobioff JD; Ferretti SE; Zangroniz P; Gamen M; Picabea E; Bessone FO; Reggiardo V; Diez AR; Tanno M; Cuesta C; Tanno HE
    Am J Gastroenterol; 2007 Oct; 102(10):2206-13. PubMed ID: 17608776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of long-term treatment with octreotide on rectal sensitivity in patients with non-constipated irritable bowel syndrome.
    Klooker TK; Kuiken SD; Lei A; Boeckxstaens GE
    Aliment Pharmacol Ther; 2007 Aug; 26(4):605-15. PubMed ID: 17661764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment with octreotide of stenosing cystic dystrophy on heterotopic pancreas of the duodenal wall].
    de Parades V; Roulot D; Palazzo L; Chaussade S; Mingaud P; Rautureau J; Coste T
    Gastroenterol Clin Biol; 1996; 20(6-7):601-4. PubMed ID: 8881576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New gastroenterological prospects of ursodeoxycholic acid].
    Sheptulin AA
    Klin Med (Mosk); 1996; 74(4):8-10. PubMed ID: 8999169
    [No Abstract]   [Full Text] [Related]  

  • 35. Octreotide in the treatment of lymphorrhea after axillary node dissection: a prospective randomized controlled trial.
    Carcoforo P; Soliani G; Maestroni U; Donini A; Inderbitzin D; Hui TT; Lefor A; Avital I; Navarra G
    J Am Coll Surg; 2003 Mar; 196(3):365-9. PubMed ID: 12648685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Somatostatin and its analogs in the treatment of gastrointestinal and liver diseases].
    Feu F; Bosch J
    Gastroenterol Hepatol; 1996 Feb; 19(2):68-77. PubMed ID: 8616683
    [No Abstract]   [Full Text] [Related]  

  • 37. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
    Toumpanakis C; Garland J; Marelli L; Srirajaskanthan R; Soh J; Davies P; Buscombe J; Caplin ME
    Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide.
    Caroli A; Antiga L; Cafaro M; Fasolini G; Remuzzi A; Remuzzi G; Ruggenenti P
    Clin J Am Soc Nephrol; 2010 May; 5(5):783-9. PubMed ID: 20185596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The liver in autosomal dominant polycystic kidney disease. Implications for pathogenesis.
    Ramos A; Torres VE; Holley KE; Offord KP; Rakela J; Ludwig J
    Arch Pathol Lab Med; 1990 Feb; 114(2):180-4. PubMed ID: 2302034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sustained release octreotide may have a role in the treatment of malignant bowel obstruction.
    Massacesi C; Galeazzi G
    Palliat Med; 2006 Oct; 20(7):715-6. PubMed ID: 17060271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.